ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes Inhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality.

ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model NLRP3 inflammasome inhibition attenuates intestinal inflammation and tissue damage, and significantly improves symptoms in IBD animal model.